Scientific Program

Presidential Lectures

New ER-targeted Therapies: SERDs, SERMs, PROTACs and SERCAs
M. P. Goetz
Practice-changing Study Results of Breast Surgery and Reconstruction
J.-U. Blohmer

Satellite Symposium with kind support of AstraZeneca

Targeting Future Perspectives in Clinical Oncology
Chairs: J. Sehouli, J.-U. Blohmer

• Strategies to Overcome Endocrine Resistance in Breast Cancer
  J.-U. Blohmer
• Combining Immunotherapy and PARP Inhibition in Gynecological Cancer
  J. Sehouli

State of the Art Session

Chairs: M. P. Goetz, O. Camara

HER2-positive Breast Cancer: Which Therapies When and for Whom?
J. K. Wagner

TNBC and Immune Checkpoint Therapies: Do We Have Predictive Factors for High Benefit?
V. Kiver

Satellite Symposium with kind support of Daiichi Sankyo

The Future Starts Today: ADCs in Breast and Women’s Cancer
Chairs: J. Sehouli, J.-U. Blohmer

• Spotlight Metastatic Breast Cancer: Established and New Treatment Options
  J.-U. Blohmer
• Rising Stars: ADCs in Gynaecological Tumors
  J. Sehouli
• Hotchair: Panel Discussion – What are the Learnings from Breast to Women’s Cancer?
  J.-U. Blohmer, J. Sehouli

Scientific Lectures

Chairs: J. K. Wagner, V. Kiver

Immune Checkpoint Therapies for ER+ Breast Cancer: New Evidence
K. Giridhar

Is Chemotherapy for Early ER+ Breast Cancer Patients Still Necessary?
S. Kümmel

Identification and Selection of Patients for Genetic Testing
S. Yadav

Hormone Replacement Therapy: Newer Evidence
S. Pruthi

Presidential Lecture

Ovarian Cancer Management: Yesterday, Today, Tomorrow
J. Ledermann

State of the Art Session

Lymph Node Resection in Primary and Relapsed Ovarian Cancer?
C. Fotopoulou

Satellite Symposium with kind support of Immunogen

ADCs in Platinum-resistant Ovarian Cancer
Chair: J. Sehouli

• Antibody-Drug Conjugates (ADCs) – A New Class in Ovarian Cancer
  P. Harter
• ADC Experience and Management: What have We Learnt? – 1 Year of ADC Experience
  K. Moore
• How to Prepare your Clinic for ADCs: Treatment and Management
  G. Konecny
• Panel Discussion and Q&A
  J. Sehouli + Speakers

Debate

HRD-related Therapies: PRIMA vs. Paola vs. Athena vs. Ov-43 vs. Duo-O and More…
What is the Best Strategy?

• Mayo Perspective: A. Wahner Hendrickson
• Charité Perspective: E. I. Braicu

Expert Panel: Can We Define a Global Consensus?
B. Monk, K. Moore, A. Wahner Hendrickson, K. Fujiwara, P. Harter, I. Ray-Coquard + Chairs

Educational Session

Prehabilitation in Ovarian Cancer

• Mayo Perspective: A. Kumar
• Charité Perspective: The Charité Priming Concept for Gynecological Cancers: J. Sehouli

Enhanced Recovery after Surgery (ERAS) (incl. Optimal Perioperative Pain Management)

• Mayo Perspective: S. Dowdy
• Charité Perspective: M. Lee

Best Supportive Care Only or Chemotherapy or a Specific Cancer Therapy?
A. Wahner Hendrickson

Presidential Lecture

Endometrial Cancer Management: Yesterday, Today, Tomorrow (incl. Targeted Therapies, ADCs)
N. Concin

Satellite Symposium with kind support of GlaxoSmithKline

Management of Endometrial Cancer 2024 – From Clinical Study to Daily Routine
Chair: J. Sehouli

• Welcome and Introduction
  J. Sehouli
• Surgery, Value of Radiotherapy, Diagnosis
  K. Pietzner
• Current Therapy Landscape, Patient’s Perspective, Management of Side Effects
  J. Sehouli
• IO + Chemotherapy; Recent Study Data; Outlook
  M. R. Mirza
• “The Berlin CMC Consensus”
  Statement of the speakers
• Summary
  J. Sehouli

Pro/Con Debate

FIGO Staging

• PRO: G. Glaser, F. Fotopoulou
• CON: M. Shahi, P. Ramirez

Lectures

• Role of PARP Inhibitors in Endometrial Cancer
  J. Sehouli
• What is the Best Therapy for Relapsed Endometrial Cancer? Chemotherapy Pretreated or Naïve?
  G. Choong
• Options and Limits of HRD Diagnostic in Endometrial Cancer
  E. I. Braicu

Panel Discussion

• ENGOT-en9/Leap-001: Pembrolizumab and Lenvatinib in Endometrial Cancer
  C. Marth
• Duo-E, Leap-001, NRG-18, RUBY, Garnet, KEYNOTE-158, KEYNOTE-775, SIENDO, PALEO and More… – How to Integrate the Recent Milestone Trials into Clinical Practice?
  M. R. Mirza, D. Lorusso, C. Marth, J. Weroha, J. Sehouli + Chairs

Presidential Lecture

Cervical Cancer Management: Yesterday, Today, Tomorrow – The Global Perspective
L. Chinula

Lectures

Revolution in Cervical Cancer Surgery? Radical Hysterectomy, Simple Hysterectomy, or Cone Biopsy in Early-stage Cervical Cancer
S. Mahner

Role of Neoadjuvant Chemotherapy in High-risk Cervical Cancer:
J. Ledermann

Surgery, Radiochemotherapy, or Incorporation of Immunotherapy in Primary Cervical Cancer?
D. Lorusso

Panel Discussion

Insights of Charité Mayo Practise and How to Translate these Data into Clinical Routine?
M. Block, J. Sehouli, F. Mehrhof, P. Wimberger, R. Armbrust + Chairs

Lectures

Newest Options with ADCs in Relapsed Cervical Cancer
I. Vergote

Phase I Data and Immunotherapy
M. Block

Closing Session

Presentation of the Three Best Posters
Closing Words and Farewell

Berlin Cultural Highlight